DOI QR코드

DOI QR Code

An Updated Meta-analysis Between the Association of XRCC1 Arg399Gln Polymorphism and Hepatocellular Carcinoma Risk

  • Zhang, Xiao-Lian (Department of Clinical Labororatory, First Affiliated Hospital of Guangxi Medical University) ;
  • Lu, Yu (Department of Clinical Labororatory, First Affiliated Hospital of Guangxi Medical University) ;
  • Yang, Shi (Department of Clinical Labororatory, First Affiliated Hospital of Guangxi Medical University) ;
  • Peng, Qi-Liu (Department of Clinical Labororatory, First Affiliated Hospital of Guangxi Medical University) ;
  • Wang, Jian (Department of Clinical Labororatory, First Affiliated Hospital of Guangxi Medical University) ;
  • Xie, Li (Department of Clinical Labororatory, First Affiliated Hospital of Guangxi Medical University) ;
  • Deng, Yan (Department of Clinical Labororatory, First Affiliated Hospital of Guangxi Medical University) ;
  • He, Yu (Department of Clinical Labororatory, First Affiliated Hospital of Guangxi Medical University) ;
  • Li, Tai-Jie (Department of Clinical Labororatory, First Affiliated Hospital of Guangxi Medical University) ;
  • Qin, Xue (Department of Clinical Labororatory, First Affiliated Hospital of Guangxi Medical University) ;
  • Li, Shan (Department of Clinical Labororatory, First Affiliated Hospital of Guangxi Medical University)
  • Published : 2014.04.01

Abstract

Background: Various studies have evaluated the relationship between X-ray repair cross-complementing group 1 (XRCC1) Arg399Gln polymorphism and hepatocellular carcinoma (HCC) risk, but the conclusions have been inconsistent and underpowered. The purpose of this updated meta-analysis was to examine whether XRCC1 Arg399Gln polymorphism confers susceptibility to HCC. Methods: Eligible studies extracted from PubMed, Embase, Cochrane Library, VIP (chinese) and CNKI (chinese) up to November 2013 were included in the study. Pooled odds ratio (OR) together with their 95% confidence interval (CI) were estimated to evaluate XRCC1 Arg399Gln polymorphism and HCC risk. Results: Finally, 21 studies with 4,170 cases and 5,030 controls were involved in our meta-analysis. The results demonstrated that there was significant association between Arg399Gln polymorphism and HCC risk under two contrast models in overall populations (AG vs GG: OR=1.265, 95%CI=1.036-1.545, p=0.021; AA+AG vs GG: OR=1.240, 95%CI=1.021-1.506, p=0.030). In subgroup analyses, significant association was found in Asians (A vs G: OR=1.175, 95%CI=1.013-1.362, p=0.033; AG vs GG: OR=1.317, 95%CI=1.070-1.622, p=0.009; AA+AG vs GG: OR=1.289, 95%CI=1.055-1.575, p=0.013) and Caucasians (A vs G: OR=0.591, 95%CI=0.361-0.966, p=0.036; AA+AG vs GG: OR=0.468, 95%CI=0.234-0.934, p=0.031). Conclusions: The results suggest that XRCC1 Arg399Gln polymorphism may increase HCC risk especially among Asians. However, XRCC1 Arg399Gln polymorphism might act as a protective role against HCC among Caucasians.

Keywords

XRCC1;polymorphism;HCC;meta-analysis;risk

References

  1. Yang JL, Han YN, Zheng SG, et al (2004). Influence of human XRCC1-399 single nucleotide polymorphism on primary hepatocytic carcinoma. Tumor, 322-4.
  2. Yu MW, Yang SY, Pan IJ, et al (2003). Polymorphisms in XRCC1 and glutathione S-transferase genes and hepatitis B-related hepatocellular carcinoma. J Natl Cancer Inst, 95, 1485-8. https://doi.org/10.1093/jnci/djg051
  3. Wu D, Jiang H, Gu Q, et al (2013). Association between XRCC1 Arg399Gln polymorphism and hepatitis virus-related hepatocellular carcinoma risk in Asian population. Tumour Biol, 34, 3265-9. https://doi.org/10.1007/s13277-013-0899-4
  4. Wu H (2009). Correlation between DNA repair gene XRCC1 single nucleotide polymorphism and susceptibility to hepatocellular carcinoma in Fusui county of Guangxi. Guangxi Medical Unibersity.
  5. Shen MR, Jones IM, Mohrenweiser H (1998). Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res, 58, 604-8.
  6. Su HY (2008). A case-control study on association between genetic polymorphisms of DNA repair and hepatic cell cancer susceptibility. China Medical University.
  7. Tang YT, Li XP, Liu TQ, et al (2011). Genetic polymorphisms of DNA repair genes in patients with hepatocellular carcinoma. Shandong Med J, 19-20.
  8. Vidal AE, Boiteux S, Hickson ID, et al (2011). XRCC1 coordinates the initial and late stages of DNA abasic site repair through protein-protein interactions. EMBO J, 20, 6530-9.
  9. Ren Y, Wang DS, Li Z, et al (2008). Study on the relationship between gene XRCC1 codon 399 single mucleotide polymorphisms and primary hepatic carcinoma in Han nationality. J Clin Hepatol, 361-4.
  10. Sato K, Mori M (2011). Evolving molecular mechanism-based strategies for control of hepatocellular carcinoma. Curr Med Chem, 18, 4375-88. https://doi.org/10.2174/092986711797200462
  11. Masson M, Niedergang C, Schreiber V, et al (1998). XRCC1 is specifically associated with poly (ADP-ribose) polymerase and negatively regulates its activity following DNA damage. Mol Cell Biol, 18, 3563-71. https://doi.org/10.1128/MCB.18.6.3563
  12. Mei J, Duan HX, Wang LL, et al (2013). XRCC1 polymorphisms and cervical cancer risk: an updated meta-analysis. Tumour Biol, 35, 1221-31.
  13. Mohana Devi S, Balachandar V, Arun M, et al (2013). Analysis of genetic damage and gene polymorphism in hepatocellular carcinoma (HCC) patients in a South Indian population. Dig Dis Sci, 58, 759-67. https://doi.org/10.1007/s10620-012-2409-8
  14. Pan HZ, Liang J, Yu Z, et al (2011), Polymorphism of DNA repair gene XRCC1 and hepatocellular carcinoma risk in Chinese population. Asian Pac J Cancer Prev, 12, 2947-50.
  15. Poehlmann A, Roessner A (2010). Importance of DNA damage checkpoints in the pathogenesis of human cancers. Pathol Res Pract,206, 591-601. https://doi.org/10.1016/j.prp.2010.06.006
  16. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
  17. Long XD, Ma Y, Wei YP, et al (2005). X-ray repair cross-complementing group 1 (xrcc1) arg 399 gln polymorphism and aflatoxin b1 (afb1)-related hepatocellular carcinoma (hcc) in guangxi population. Chinese J Cancer Res, 17-21.
  18. Long XD, Ma Y, Wei YP, et al (2006). The polymorphisms of GSTM1, GSTT1, HYL1*2, and XRCC1, and aflatoxin B1-related hepatocellular carcinoma in Guangxi population, China. Hepatol Res, 36, 48-55. https://doi.org/10.1016/j.hepres.2006.06.004
  19. Long XD, Ma Y, Wei YP, et al (2004). Polymorphism of DNA repair gene XRCC1 and risk of hepatocellular carcinoma. J Guangxi Medical University, 313-5.
  20. Li S, Peng Q, Chen Y, et al (2013). DNA repair gene XRCC1 polymorphisms, smoking, and bladder cancer risk: A meta-analysis. PLoS One, 8, 73448. https://doi.org/10.1371/journal.pone.0073448
  21. Kirk GD, Turner PC, Gong Y, et al (2005). Hepatocellular carcinoma and polymorphisms in carcinogen-metabolizing and DNA repair enzymes in a population with aflatoxin exposure and hepatitis B virus endemicity. Cancer Epidemion Biomarders Prev, 14, 373-9. https://doi.org/10.1158/1055-9965.EPI-04-0161
  22. Li J, Li Z, Feng L, et al (2013). Polymorpisms of DNA repair gene XRCC1 and hepatocellular carcinoma risk among East Asians: a meta-analysis. Tumour Biol, 34, 261-9. https://doi.org/10.1007/s13277-012-0546-5
  23. Li QW, Lu CR, Ye M, et al (2012). Evaluation of DNA repair gene XRCC1 polymorphism in prediction and prognosis of hepatocellular carcinoma risk. Asian Pac J Cancer Prev, 13, 191-4. https://doi.org/10.7314/APJCP.2012.13.1.191
  24. Jung SW, Park NH, Shin JW, et al (2012). Polymorphisms of DNA repair genes in Korean hepatocellular carcinoma patients with chronic hepatitis B: possible implications on survival. J Hepatol, 57, 621-7. https://doi.org/10.1016/j.jhep.2012.04.039
  25. Kiran M, Saxena R, Chawla YK, et al (2009). Polymorphism of DNA repair gene XRCC1 and hepatitis-related hepatocellular carcinoma risk in Indian population. Mol Cell Biochem, 327, 7-13. https://doi.org/10.1007/s11010-009-0035-3
  26. Caldwell, Park SH (2009). The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology. J Gastroenterol, 44, 96-101. https://doi.org/10.1007/s00535-008-2258-6
  27. Chen CC, Yang SY, Liu CJ, et al (2005). Association of cytokine and DNA repair gene polymorphisms with hepatitis B-related hepatocellular carcinoma. Int J Epidemiol, 34, 1310-8. https://doi.org/10.1093/ije/dyi191
  28. Borentain P, Gerolami V, Ananian P, et al (2007). DNA-repair and carcinogen-metabolising enzymes genetic polymorphisms as an independent risk factor for hepatocellular carcinoma in Caucasian liver-transplanted. Eur J Cancer, 43, 2479-86. https://doi.org/10.1016/j.ejca.2007.08.006
  29. Bose S, Tripathi DM, Sukriti, et al (2013). Genetic polymorphisms of CYP2E1 and DNA repair genes HOGG1 and XRCC1: association with hepatitis B related advanced liver disease and cancer. Gene, 519, 231-7. https://doi.org/10.1016/j.gene.2013.02.025
  30. Zeng XY, Yu HP, Qiu XQ, et al (2010). A case-control study of polymorphism of XRCC1 gene and the risk of hepatocellular carcinoma. Chinese J Disease Control Prevent, 760-3.
  31. Zhang H, Wang P, Dai L, et al (2010). Meta-analysis of the relationship between polymorphisms of 399 point of X-ray repair cross complementing gene group 1 and hepatocellular carcinoma. Wei Sheng Yan Jiu, 39, 664-8.
  32. Jia F, Su H, Li X (2010). Polymorhisms of UGT1A7 and XRCC1 are Associated with an Increased Risk of Hepatocellular Carcinoma in Northeast China. Chinese J Cancer Res, 260-6.
  33. Hoeijmakers JH (2001). Genome maintenance mechanisms for preventing cancer. Nature, 411, 366-74. https://doi.org/10.1038/35077232
  34. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  35. Higgins JP, Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Stat Med, 21, 1539-58. https://doi.org/10.1002/sim.1186
  36. Higgins JP, Thompson SG, Deeks JJ, et al (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60. https://doi.org/10.1136/bmj.327.7414.557
  37. He GZ, Hung TR, Deng W, et al (2012). Research on Association Between XRCC1 Arg399Gln Polymorphism and Liver Cancer. Journal of Guangxi University Of Chnese Medicine, 1-3.
  38. Han X, Xing Q, Li Y, et al (2012). Study on the DNA repair gene XRCC1 and XRC3 polymorphism in prediction and prognosis of hepatocellular carcinoma risk. Hepatogastroenterology, 59, 2285-9.
  39. Han YN, Yang JL, Zheng SG, et al (2004). Study on the association of human XRCC1-399 single nucleotide polymorphism and primary hepatocytic carcinoma. Chinese Hepatology, 235-7.
  40. Gulnaz A, Sayyed AH, Amin F, et al (2013). Association of XRCC1, XRCC3, and XPD genetic polymorphism with an increased risk of hepatocellular carcinoma because of the hepatitis B and C virus. Eur J Gastroenterol Hepatol, 25, 166-79. https://doi.org/10.1097/MEG.0b013e328359a775
  41. Guo LY, Jin XP, Niu W, et al (2012). Association of XPD and XRCC1 genetic polymorphisms with hepatocellular carcinoma risk. Asian Pac J Cancer Prev, 13, 4423-6. https://doi.org/10.7314/APJCP.2012.13.9.4423
  42. Hagymasi K, Tulassay Z (2008). [Epidemiology, risk facors and molecular pathogenesis of primary liver cancer]. Orv Hetil, 149, 541-8 (in Hungarian). https://doi.org/10.1556/OH.2008.28313
  43. Farazi PA, DePinho RA (2006). Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer, 6, 674-87. https://doi.org/10.1038/nrc1934
  44. Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917. https://doi.org/10.1002/ijc.25516
  45. Forner A, Llovet JM, Bruix J (2012). Hepatocellular carcinoma. Lancet, 379, 1245-55. https://doi.org/10.1016/S0140-6736(11)61347-0
  46. Gomaa AI, Khan SA, Toledano MB, et al (2008). Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol, 14, 4300-8. https://doi.org/10.3748/wjg.14.4300
  47. Egger M, Davey Smih G, Schneider M, et al (1997). Bias in meta-analysis betected by a simple, graphical test. BMJ, 315, 629-34. https://doi.org/10.1136/bmj.315.7109.629
  48. El-Serag HB (2011). Hepatocellular carcinoma. N Engl J Med, 365, 1118-27. https://doi.org/10.1056/NEJMra1001683
  49. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88. https://doi.org/10.1016/0197-2456(86)90046-2
  50. Ding F, Chen YY, Xie Y, et al (2012). Correlation between XRCC1 genetic Polymorphism Arg399Gln and susceptibility to hepatocellular carcinoma in liver caner family clusters in Fusui county, Guangxi. Chinese J Oncol preve Treat, 33-7.
  51. Almeida KH, Sobol RW (2007). A unified view of base excision repair: lesion-dependent protein complexes regulated by post-translational modification. DNA Repair, 6, 695-711. https://doi.org/10.1016/j.dnarep.2007.01.009

Cited by

  1. IL28B rs12979860 Gene Polymorphism in Egyptian Patients with Chronic Liver Disease Infected with HCV vol.15, pp.17, 2014, https://doi.org/10.7314/APJCP.2014.15.17.7213
  2. XRCC1 Gene Polymorphism, Diet and Risk of Colorectal Cancer in Thailand vol.15, pp.17, 2014, https://doi.org/10.7314/APJCP.2014.15.17.7479
  3. Independent and Additive Interaction Between Tumor Necrosis Factor β +252 Polymorphisms and Chronic Hepatitis B and C Virus Infection on Risk and Prognosis of Hepatocellular Carcinoma: a Case-Control Study vol.15, pp.23, 2015, https://doi.org/10.7314/APJCP.2014.15.23.10209
  4. Polymorphisms in Predicting Prognosis of Hepatocellular Carcinoma in Patients Receiving Transcatheter Arterial Chemoembolization vol.20, pp.4, 2016, https://doi.org/10.1089/gtmb.2015.0267
  5. Quantitative assessment of the association between XRCC1 Arg399Gln and Arg194Trp polymorphisms and risk of cutaneous melanoma vol.26, pp.3, 2016, https://doi.org/10.1097/CMR.0000000000000246
  6. The Relationship Between Single-Nucleotide Polymorphisms, the Expression of DNA Damage Response Genes, and Hepatocellular Carcinoma in a Polish Population vol.36, pp.8, 2017, https://doi.org/10.1089/dna.2017.3664
  7. XRCC1 polymorphism and overall survival in ovarian cancer patients treated with platinum-based chemotherapy vol.97, pp.45, 2018, https://doi.org/10.1097/MD.0000000000012996